Mylonakis, Eleftherios

Medically important bacterial-fungal interactions

Peleg, A. Y., Hogan, D. A., & Mylonakis, E. (2010) · Nature Reviews Microbiology

Antifungal resistance and susceptibilityGut microbiota and health

Cited by 619

Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease

Cowen, L. E., Singh, S. D., Köhler, J. R., Collins, C., Zaas, A. K., Schell, W. A., Aziz, H., Mylonakis, E., Perfect, J. R., Whitesell, L., et al. (2009) · Proceedings of the National Academy of Sciences

Antifungal resistance and susceptibilityHeat shock proteins research

Cited by 413

A nuclear receptor-like pathway regulating multidrug resistance in fungi

Thakur, J. K., Arthanari, H., Yang, F., Pan, S.-J., Fan, X., Breger, J., Frueh, D. P., Gulshan, K., Li, D. K., Mylonakis, E., et al. (2008) · Nature

Fungal and yeast genetics researchAntifungal resistance and susceptibility

Cited by 343

Our paths might cross: the role of the fungal cell wall integrity pathway in stress response and cross talk with other stress response pathways

Fuchs, B. B., & Mylonakis, E. (2009) · Eukaryotic Cell

Fungal and yeast genetics researchAntifungal resistance and susceptibility

Cited by 266

Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial

Thompson, G. R., Soriano, A., Cornely, O. A., Kullberg, B. J., Kollef, M., Vazquez, J., Honore, P. M., Bassetti, M., Pullman, J., Chayakulkeeree, M., et al. (2023) · The Lancet

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 192

Loss of cell wall alpha(1‐3) glucan affects Cryptococcus neoformans from ultrastructure to virulence

Reese, A. J., Yoneda, A., Breger, J. A., Beauvais, A., Liu, H., Griffith, C. L., Bose, I., Kim, M., Skau, C., Yang, S., et al. (2007) · Molecular Microbiology

Fungal Infections and StudiesFungal and yeast genetics research

Cited by 183

Emerging Technologies for Use in the Study, Diagnosis, and Treatment of Patients with COVID-19

Tsikala Vafea, M., Atalla, E., Georgakas, J., Shehadeh, F., Mylona, E. K., Kalligeros, M., & Mylonakis, E. (2020) · Cellular and Molecular Bioengineering

Healthcare during COVID-19 PandemicArtificial Intelligence in Healthcare and Education

Cited by 153

Candida parapsilosis Resistance to Fluconazole: Molecular Mechanisms and In Vivo Impact in Infected Galleria mellonella Larvae

Souza, A. C. R., Fuchs, B. B., Pinhati, H. M. S., Siqueira, R. A., Hagen, F., Meis, J. F., Mylonakis, E., & Colombo, A. L. (2015) · Antimicrobial Agents and Chemotherapy

Antifungal resistance and susceptibilityFungal and yeast genetics research

Cited by 121

Innate Recognition of Cell Wall β-Glucans Drives Invariant Natural Killer T Cell Responses against Fungi

Cohen, N. R., Tatituri, R. V. V., Rivera, A., Watts, G. F. M., Kim, E. Y., Chiba, A., Fuchs, B. B., Mylonakis, E., Besra, G. S., Levitz, S. M., et al. (2011) · Cell Host & Microbe

Immune Response and InflammationT-cell and B-cell Immunology

Cited by 115

MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis

Spec, A., Pullman, J., Thompson, G. R., Powderly, W. G., Tobin, E. H., Vazquez, J., Wring, S. A., Angulo, D., Helou, S., Pappas, P. G., et al. (2019) · Journal of Antimicrobial Chemotherapy

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 88

Reconstructed apoptotic bodies as targeted "nano decoys" to treat intracellular bacterial infections within macrophages and cancer cells

Bose, R. J. C., Tharmalingam, N., Garcia Marques, F. J., Sukumar, U. K., Natarajan, A., Zeng, Y., Robinson, E., Bermudez, A., Chang, E., Habte, F., et al. (2020) · ACS Nano

Nanoparticle-Based Drug DeliveryBacterial Cancer Therapy

Cited by 84

Colonisation with extended-spectrum β-lactamase-producing Enterobacteriaceae and risk for infection among patients with solid or haematological malignancy: a systematic review and meta-analysis

Alevizakos, M., Karanika, S., Detsis, M., & Mylonakis, E. (2016) · International Journal of Antimicrobial Agents

Antibiotic Resistance in BacteriaNeutropenia and Cancer Infections

Cited by 77

Eca1, a Sarcoplasmic/Endoplasmic Reticulum Ca2+-ATPase, Is Involved in Stress Tolerance and Virulence in Cryptococcus neoformans

Fan, W., Idnurm, A., Breger, J., Mylonakis, E., & Heitman, J. (2007) · Infection and Immunity

Fungal Infections and StudiesFungal and yeast genetics research

Cited by 57

A Systematic Review and Meta-analysis of Antibiotic Treatment Duration for Bacteremia Due to Enterobacteriaceae

Tansarli, G. S., Andreatos, N., Pliakos, E. E., & Mylonakis, E. (2019) · Antimicrobial Agents and Chemotherapy

Antibiotics Pharmacokinetics and EfficacyAntibiotic Use and Resistance

Cited by 56

Diagnosis of invasive aspergillosis: recent developments and ongoing challenges

Arvanitis, M., & Mylonakis, E. (2015) · European Journal of Clinical Investigation

Antifungal resistance and susceptibilityFungal and yeast genetics research

Cited by 56

Correlation of opioid mortality with prescriptions and social determinants: a cross-sectional study of medicare enrollees

Grigoras, C. A., Karanika, S., Velmahos, E., Alevizakos, M., Flokas, M.-E., Kaspiris-Rousellis, C., Evaggelidis, I.-N., Artelaris, P., Siettos, C. I., & Mylonakis, E. (2018) · Drugs

Opioid Use Disorder TreatmentPain Management and Opioid Use

Cited by 37

Statin therapy and decreased incidence of positive Candida cultures among patients with type 2 diabetes mellitus undergoing gastrointestinal surgery.

Spanakis, E. K., Kourkoumpetis, T. K., Livanis, G., Peleg, A. Y., & Mylonakis, E. (2010) · Mayo Clinic Proceedings

Antifungal resistance and susceptibilityCancer, Lipids, and Metabolism

Cited by 31